PURPOSE: Altered expression of serine protease inhibitor peptidase inhibitor clade E member 2 (SERPINE2) associates with human cancer development and progression; thus, this study investigated SERPINE2 expression in gastric cancer tissues for association with clinicopathological and survival data from the patients and then investigated the role of SERPINE2 in gastric cancer cells in vitro. METHODS: The levels of SERPINE2 mRNA in 243 gastric cancer tissues and paired non-cancerous mucosa were determined using quantitative PCR. Inhibition of SERPINE2 expression by small interfering RNA (siRNA) was detected by Western blotting. tetrazolium, soft agar, and transwell assays were performed to evaluate the proliferation, anchorage-independent growth, and motility of gastric cancer SGC7901 cells transfected with SERPINE2 siRNA. RESULTS: Compared with the normal mucosa, SERPINE2 mRNA was increased in gastric cancer tissues and cells. Analysis of the 243 matched specimens showed that high SERPINE2 levels were associated with lymph node metastasis, distant metastasis, and clinical stage. Patients with high SERPINE2 mRNA levels had poorer survival compared with patients with low SERPINE2 mRNA levels. In vitro, SERPINE2 inhibited anchorage-independent growth, migration, and invasion of SGC7901 cells, but not proliferation. CONCLUSIONS: Our findings indicate that upregulated SERPINE2 may contribute to the aggressive phenotype of gastric cancer and suggest that SERPINE2 can be used as a novel prognostic factor and anticancer target in patients with gastric cancer.
PURPOSE: Altered expression of serine protease inhibitor peptidase inhibitor clade E member 2 (SERPINE2) associates with humancancer development and progression; thus, this study investigated SERPINE2 expression in gastric cancer tissues for association with clinicopathological and survival data from the patients and then investigated the role of SERPINE2 in gastric cancer cells in vitro. METHODS: The levels of SERPINE2 mRNA in 243 gastric cancer tissues and paired non-cancerous mucosa were determined using quantitative PCR. Inhibition of SERPINE2 expression by small interfering RNA (siRNA) was detected by Western blotting. tetrazolium, soft agar, and transwell assays were performed to evaluate the proliferation, anchorage-independent growth, and motility of gastric cancer SGC7901 cells transfected with SERPINE2 siRNA. RESULTS: Compared with the normal mucosa, SERPINE2 mRNA was increased in gastric cancer tissues and cells. Analysis of the 243 matched specimens showed that high SERPINE2 levels were associated with lymph node metastasis, distant metastasis, and clinical stage. Patients with high SERPINE2 mRNA levels had poorer survival compared with patients with low SERPINE2 mRNA levels. In vitro, SERPINE2 inhibited anchorage-independent growth, migration, and invasion of SGC7901 cells, but not proliferation. CONCLUSIONS: Our findings indicate that upregulated SERPINE2 may contribute to the aggressive phenotype of gastric cancer and suggest that SERPINE2 can be used as a novel prognostic factor and anticancer target in patients with gastric cancer.
Authors: Dawn DeMeo; Thomas Mariani; Christoph Lange; Stephen Lake; Augusto Litonjua; Juan Celedón; John Reilly; Harold A Chapman; David Sparrow; Avrum Spira; Jennifer Beane; Victor Pinto-Plata; Frank E Speizer; Steve Shapiro; Scott T Weiss; Edwin K Silverman Journal: Proc Am Thorac Soc Date: 2006-08
Authors: Chad M McKee; Danmei Xu; Yunhong Cao; Sheheryar Kabraji; Danny Allen; Veerle Kersemans; John Beech; Sean Smart; Freddie Hamdy; Adrian Ishkanian; Jenna Sykes; Melania Pintile; Michael Milosevic; Theodorus van der Kwast; Gaetano Zafarana; Varune Rohan Ramnarine; Igor Jurisica; Chad Mallof; Wan Lam; Robert G Bristow; Ruth J Muschel Journal: J Clin Invest Date: 2012-10-08 Impact factor: 14.808
Authors: Shan Gao; Annelise Krogdahl; Jens Ahm Sørensen; Tina M Kousted; Erik Dabelsteen; Peter A Andreasen Journal: Oral Oncol Date: 2007-04-30 Impact factor: 5.337
Authors: Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke Journal: Cancer Lett Date: 2020-01-31 Impact factor: 8.679
Authors: Catherine Vaillant; Paola Valdivieso; Sandro Nuciforo; Marcel Kool; Alexandra Schwarzentruber-Schauerte; Hélène Méreau; Erik Cabuy; Johannes A Lobrinus; Stefan Pfister; Aimée Zuniga; Stephan Frank; Rolf Zeller Journal: PLoS One Date: 2015-04-22 Impact factor: 3.240
Authors: Johanna Eriksson; Vadim Le Joncour; Pirjo Nummela; Tiina Jahkola; Susanna Virolainen; Pirjo Laakkonen; Olli Saksela; Erkki Hölttä Journal: Oncotarget Date: 2016-03-22
Authors: M Perego; M Maurer; J X Wang; S Shaffer; A C Müller; K Parapatics; L Li; D Hristova; S Shin; F Keeney; S Liu; X Xu; A Raj; J K Jensen; K L Bennett; S N Wagner; R Somasundaram; M Herlyn Journal: Oncogene Date: 2017-09-18 Impact factor: 9.867
Authors: E M Langer; N D Kendsersky; C J Daniel; G M Kuziel; C Pelz; K M Murphy; M R Capecchi; R C Sears Journal: Oncogene Date: 2017-10-30 Impact factor: 9.867
Authors: Tomasz Stępień; Mateusz Brożyna; Krzysztof Kuzdak; Ewelina Motylewska; Jan Komorowski; Henryk Stępień; Hanna Ławnicka Journal: Dis Markers Date: 2017-01-31 Impact factor: 3.434
Authors: Yichao Li; Sushil K Jaiswal; Rupleen Kaur; Dana Alsaadi; Xiaoyu Liang; Frank Drews; Julie A DeLoia; Thomas Krivak; Hanna M Petrykowska; Valer Gotea; Lonnie Welch; Laura Elnitski Journal: BMC Cancer Date: 2021-07-03 Impact factor: 4.430